Midatech Pharma to Acquire DARA BioSciences

Merck & Co. Acquires Cidara Therapeutics

January 8, 2026

Biotechnology

Merck & Co., through subsidiary Merck Sharp & Dohme LLC, completed a cash tender offer to acquire Cidara Therapeutics, Inc. for $221.50 per share, making Cidara a wholly owned subsidiary. The acquisition adds Cidara's long-acting antiviral candidate CD388 to Merck's respiratory portfolio and is being accounted for as an asset acquisition.

Valo Health Acquires TARA Biosystems

April 5, 2022

Biotechnology

Valo Health has acquired TARA Biosystems, a New York City–based company specializing in human 3D tissue engineering and cardiac disease modeling, to create an integrated cardiovascular drug discovery and development platform. The deal combines TARA's in vitro cardiac models with Valo's Opal computational platform to expand Valo's capabilities in cardiovascular drug discovery and accelerate development of new therapies.

Day One Biopharmaceuticals Acquires Mersana Therapeutics

January 6, 2026

Biotechnology

Day One Biopharmaceuticals (Nasdaq: DAWN) completed its acquisition of Mersana Therapeutics (Nasdaq: MRSN) via a tender offer, purchasing all outstanding shares for $25 per share in cash plus one non-tradable contingent value right (CVR) per share for up to $30.25 in milestone payments (total consideration up to $55.25 per share). The deal adds Mersana’s clinical-stage ADC emiltatug ledadotin (Emi-Le) targeting adenoid cystic carcinoma (ACC) to Day One’s pipeline; Mersana will become a wholly owned subsidiary and its shares will be delisted from Nasdaq.

Medix Biochemica Group Acquires Bioresource Technology (BRT)

June 21, 2022

Biotechnology

Medix Biochemica has acquired a 100% stake in US-based Bioresource Technology (BRT) to expand its base matrix capabilities and strengthen its presence in the United States. BRT will be integrated into Medix Biochemica’s IVD Biomaterials Business Unit (St. Louis) while operations continue in Weston, Florida, and BRT leadership will serve as strategic advisors.

Thomas H. Lee Partners and Frazier Healthcare Partners Acquire Adare Pharmaceuticals

September 22, 2020

Pharmaceuticals

Thomas H. Lee Partners and Frazier Healthcare Partners have acquired Adare Pharmaceuticals (to be rebranded Adare Pharma Solutions) from TPG Capital. The deal includes Adare’s CDMO, pharmaceutical technology and microbiome businesses while TPG retained rights to an EoE product spun into a separate entity; terms were not disclosed.

Laboratoires SERB (Charterhouse-backed) to acquire BTG Specialty Pharmaceuticals from Boston Scientific

December 1, 2020

Pharmaceuticals

Charterhouse Capital Partners–backed Laboratoires SERB has agreed to acquire BTG Specialty Pharmaceuticals from Boston Scientific. The deal expands SERB’s portfolio of emergency and critical‑care medicines (including CroFab, DigiFab and Voraxaze), strengthening its manufacturing capabilities and global commercial reach.